VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Liso-cel for aggressive B-cell NHL

Raul Cordoba, MD, PhD, of University Hospital Fundación Jiménez Díaz, Madrid, Spain, discusses results from the Phase II TRANSCEND-PILOT-017006 study (NCT03483103) evaluating lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, in relapsed/refractory large B-cell non-Hodgkin lymphoma (NHL) patients. Specifically discussed is the potential impact of this CAR T-cell therapy on elderly, unfit patients with comorbidities. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter